By vgreene, 13 April, 2021 Peds 100 effective in adolescents 12 15 yo per phase 3 trial additional studies for other age groups ongoing
By vgreene, 13 April, 2021 Primary series 12 yo 2 doses 30 g 21 days apart in moderately severely immunocompromised pts give 3rd dose 30 g 28 days after 2nd dose may consider delaying 2nd dose until 8wk after 1st dose in immunocompetent pts
By vgreene, 13 April, 2021 Type mRNA vaccine encodes for viral proteins uses host machinery to produce solitary viral proteins to induce immune response does not produce whole virus
